DAFNA Capital Management’s Century Therapeutics IPSC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.5M Sell
2,434,353
-359,233
-13% -$755K 1.25% 21
2025
Q4
$2.78M Buy
2,793,586
+1,089,354
+64% +$665K 0.65% 38
2025
Q3
$849K Hold
1,704,232
0.21% 61
2025
Q2
$952K Hold
1,704,232
0.26% 60
2025
Q1
$811K Hold
1,704,232
0.23% 64
2024
Q4
$1.72M Hold
1,704,232
0.44% 45
2024
Q3
$2.91M Hold
1,704,232
0.69% 38
2024
Q2
$4.35M Buy
1,704,232
+396,825
+30% +$1.25M 1.04% 28
2024
Q1
$5.46M Hold
1,307,407
1.24% 26
2023
Q4
$4.34M Hold
1,307,407
1.04% 32
2023
Q3
$2.61M Hold
1,307,407
0.81% 33
2023
Q2
$4.13M Hold
1,307,407
1.13% 27
2023
Q1
$4.54M Buy
1,307,407
+832,040
+175% +$3.65M 1.36% 27
2022
Q4
$2.44M Hold
475,367
0.69% 40
2022
Q3
$4.7M Hold
475,367
1.26% 26
2022
Q2
$3.99M Buy
475,367
+218,475
+85% +$2.14M 1.09% 29
2022
Q1
$3.23M Buy
256,892
+156,757
+157% +$2.08M 0.84% 33
2021
Q4
$1.59M Buy
100,135
+20,135
+25% +$378K 0.4% 50
2021
Q3
$2.01M Hold
80,000
0.53% 46
2021
Q2
$2.35M Buy
+80,000
New +$2.03M 0.49% 44

Other funds holding IPSC

DAFNA Capital Management's IPSC Position: Q1 2026 in Review

DAFNA Capital Management reduced its Century Therapeutics (IPSC) stake by 13% in Q1 2026, selling an estimated $755K and leaving 2,434,353 shares worth $5.5M. The position accounts for 1.25% of the portfolio, ranked #21.

DAFNA Capital Management first reported a position in IPSC in Q2 2021 and has held it in 20 quarters since. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • DAFNA Capital Management held 2,434,353 shares of Century Therapeutics worth $5.5M as of Q1 2026.
  • DAFNA Capital Management sold 359,233 Century Therapeutics shares in Q1 2026, an estimated $755K.
  • Century Therapeutics made up 1.25% of DAFNA Capital Management's portfolio in Q1 2026, its #21 holding.
  • DAFNA Capital Management first reported a position in Century Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.